Nuo Therapeutics, Inc. (AURX)
USD 1.35
(-1.46%)
USD 1.35
(-1.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.16 Million USD | 4.59% |
| 2022 | -3.32 Million USD | -3562.29% |
| 2021 | -90.67 Thousand USD | 76.02% |
| 2020 | -378.05 Thousand USD | 60.99% |
| 2019 | -969.19 Thousand USD | 35.59% |
| 2018 | -1.5 Million USD | 90.31% |
| 2017 | -15.53 Million USD | -85.55% |
| 2016 | -8.37 Million USD | 79.74% |
| 2015 | -41.31 Million USD | -76.65% |
| 2014 | -23.39 Million USD | -29.27% |
| 2013 | -18.09 Million USD | -40.33% |
| 2012 | -12.89 Million USD | -266.92% |
| 2011 | -3.51 Million USD | 34.96% |
| 2010 | -5.4 Million USD | -56.63% |
| 2009 | -3.44 Million USD | 56.3% |
| 2008 | -7.89 Million USD | -47.47% |
| 2007 | -5.35 Million USD | -28.7% |
| 2006 | -4.15 Million USD | 44.14% |
| 2005 | -7.44 Million USD | 9.06% |
| 2004 | -8.18 Million USD | -98.18% |
| 2003 | -4.13 Million USD | -104.7% |
| 2002 | -2.01 Million USD | 62.78% |
| 2001 | -5.42 Million USD | 83.8% |
| 2000 | -33.46 Million USD | -440.89% |
| 1999 | -6.18 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -709.25 Thousand USD | -8.76% |
| 2024 Q2 | -541.98 Thousand USD | 23.58% |
| 2023 FY | -3.16 Million USD | 4.59% |
| 2023 Q2 | -871.42 Thousand USD | -1.9% |
| 2023 Q1 | -855.19 Thousand USD | 11.21% |
| 2023 Q3 | -789.53 Thousand USD | 9.4% |
| 2023 Q4 | -652.11 Thousand USD | 17.41% |
| 2022 Q1 | -521.81 Thousand USD | -628.27% |
| 2022 FY | -3.32 Million USD | -3562.29% |
| 2022 Q4 | -963.18 Thousand USD | -5.63% |
| 2022 Q3 | -911.86 Thousand USD | 1.28% |
| 2022 Q2 | -923.72 Thousand USD | -77.02% |
| 2021 Q2 | -6546.00 USD | -14.42% |
| 2021 Q1 | -5721.00 USD | 98.23% |
| 2021 Q4 | -71.65 Thousand USD | -961.35% |
| 2021 Q3 | -6751.00 USD | -3.13% |
| 2021 FY | -90.67 Thousand USD | 76.02% |
| 2020 FY | -378.05 Thousand USD | 60.99% |
| 2020 Q3 | -6254.00 USD | 0.0% |
| 2020 Q4 | -323.63 Thousand USD | -5074.83% |
| 2019 FY | -969.19 Thousand USD | 35.59% |
| 2019 Q2 | -392.44 Thousand USD | 35.86% |
| 2019 Q3 | -38.69 Thousand USD | 90.14% |
| 2019 Q4 | 73.77 Thousand USD | 290.66% |
| 2019 Q1 | -611.83 Thousand USD | -488.51% |
| 2018 Q4 | 157.48 Thousand USD | 138.24% |
| 2018 FY | -1.5 Million USD | 90.31% |
| 2018 Q1 | -667.72 Thousand USD | 92.2% |
| 2018 Q3 | -411.79 Thousand USD | 29.33% |
| 2018 Q2 | -582.66 Thousand USD | 12.74% |
| 2017 Q3 | -1.37 Million USD | 24.92% |
| 2017 FY | -15.53 Million USD | -85.55% |
| 2017 Q1 | -1.68 Million USD | 15.62% |
| 2017 Q2 | -1.83 Million USD | -8.7% |
| 2017 Q4 | -8.56 Million USD | -522.71% |
| 2016 Q3 | -1.85 Million USD | 6.2% |
| 2016 Q1 | -1.97 Million USD | 68.43% |
| 2016 Q2 | -1.97 Million USD | -0.23% |
| 2016 FY | -8.37 Million USD | 79.74% |
| 2016 Q4 | -1.99 Million USD | -7.59% |
| 2015 FY | -41.31 Million USD | -76.65% |
| 2015 Q4 | -6.25 Million USD | 77.06% |
| 2015 Q3 | -27.25 Million USD | -514.35% |
| 2015 Q2 | -4.43 Million USD | -31.63% |
| 2015 Q1 | -3.37 Million USD | 23.75% |
| 2014 Q2 | -9.82 Million USD | -111.23% |
| 2014 Q3 | -4.49 Million USD | 54.21% |
| 2014 Q4 | -4.42 Million USD | 1.7% |
| 2014 FY | -23.39 Million USD | -29.27% |
| 2014 Q1 | -4.65 Million USD | -21.71% |
| 2013 Q2 | -4.66 Million USD | 6.83% |
| 2013 Q4 | -3.82 Million USD | 17.12% |
| 2013 FY | -18.09 Million USD | -40.33% |
| 2013 Q1 | -5 Million USD | -38.26% |
| 2013 Q3 | -4.6 Million USD | 1.12% |
| 2012 FY | -12.89 Million USD | -266.92% |
| 2012 Q3 | -4.2 Million USD | -79.18% |
| 2012 Q2 | -2.34 Million USD | 13.64% |
| 2012 Q1 | -2.71 Million USD | -1239.69% |
| 2012 Q4 | -3.61 Million USD | 14.01% |
| 2011 FY | -3.51 Million USD | 34.96% |
| 2011 Q2 | -1.23 Million USD | 16.51% |
| 2011 Q3 | -1.03 Million USD | 16.62% |
| 2011 Q4 | 238.61 Thousand USD | 123.12% |
| 2011 Q1 | -1.48 Million USD | 0.57% |
| 2010 FY | -5.4 Million USD | -56.63% |
| 2010 Q4 | -1.49 Million USD | -15.5% |
| 2010 Q3 | -1.29 Million USD | 17.23% |
| 2010 Q1 | -1.06 Million USD | 3.03% |
| 2010 Q2 | -1.55 Million USD | -47.06% |
| 2009 Q1 | -897.66 Thousand USD | 81.02% |
| 2009 Q2 | -890.48 Thousand USD | 0.8% |
| 2009 Q4 | -1.09 Million USD | -92.78% |
| 2009 Q3 | -567.43 Thousand USD | 36.28% |
| 2009 FY | -3.44 Million USD | 56.3% |
| 2008 Q3 | -903.6 Thousand USD | 30.2% |
| 2008 Q2 | -1.29 Million USD | -33.86% |
| 2008 Q1 | -967.07 Thousand USD | 16.36% |
| 2008 FY | -7.89 Million USD | -47.47% |
| 2008 Q4 | -4.72 Million USD | -423.33% |
| 2007 Q4 | -1.15 Million USD | 55.86% |
| 2007 FY | -5.35 Million USD | -28.7% |
| 2007 Q1 | -938.66 Thousand USD | -3.78% |
| 2007 Q3 | -2.61 Million USD | -270.28% |
| 2007 Q2 | -707.43 Thousand USD | 24.63% |
| 2006 Q1 | -1.24 Million USD | -25.45% |
| 2006 Q3 | -1.09 Million USD | -19.73% |
| 2006 Q4 | -904.47 Thousand USD | 17.5% |
| 2006 FY | -4.15 Million USD | 44.14% |
| 2006 Q2 | -915.72 Thousand USD | 26.31% |
| 2005 FY | -7.44 Million USD | 9.06% |
| 2005 Q1 | -1.89 Million USD | -2.47% |
| 2005 Q4 | -990.57 Thousand USD | 58.95% |
| 2005 Q3 | -2.41 Million USD | -12.28% |
| 2005 Q2 | -2.14 Million USD | -13.55% |
| 2004 Q1 | -2.45 Million USD | -80.92% |
| 2004 Q4 | -1.84 Million USD | 0.63% |
| 2004 Q3 | -1.85 Million USD | 8.43% |
| 2004 Q2 | -2.03 Million USD | 17.21% |
| 2004 FY | -8.18 Million USD | -98.18% |
| 2003 Q4 | -1.35 Million USD | -36.48% |
| 2003 FY | -4.13 Million USD | -104.7% |
| 2003 Q3 | -993.05 Thousand USD | 10.27% |
| 2003 Q2 | -1.1 Million USD | -63.57% |
| 2003 Q1 | -676.61 Thousand USD | -267.82% |
| 2002 FY | -2.01 Million USD | 62.78% |
| 2002 Q3 | -856.89 Thousand USD | -59.41% |
| 2002 Q4 | -183.95 Thousand USD | 78.53% |
| 2002 Q2 | -537.55 Thousand USD | -22.15% |
| 2002 Q1 | -440.06 Thousand USD | -19.31% |
| 2001 Q2 | -2.12 Million USD | 10.92% |
| 2001 Q4 | -368.84 Thousand USD | 60.54% |
| 2001 Q3 | -934.75 Thousand USD | 55.97% |
| 2001 Q1 | -2.38 Million USD | 87.14% |
| 2001 FY | -5.42 Million USD | 83.8% |
| 2000 Q3 | -5.09 Million USD | -51.99% |
| 2000 Q2 | -3.35 Million USD | 48.33% |
| 2000 Q1 | -6.48 Million USD | 0.0% |
| 2000 Q4 | -18.53 Million USD | -263.73% |
| 2000 FY | -33.46 Million USD | -440.89% |
| 1999 FY | -6.18 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -137.247% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 37.193% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 82.248% |
| Nascent Biotech, Inc. | -2.22 Million USD | -42.083% |
| Rebus Holdings, Inc. | -664 Thousand USD | -377.15% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.871% |
| Qrons Inc. | -643.67 Thousand USD | -392.215% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -713.275% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 94.292% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -662.559% |
| Skye Bioscience, Inc. | -13.67 Million USD | 76.826% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 95.587% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 164.464% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1110.531% |
| SQZ Biotechnologies Company | -75.82 Million USD | 95.822% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -11.148% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -106.261% |
| Mesoblast Limited | -84.14 Million USD | 96.235% |
| Marizyme, Inc. | -34.08 Million USD | 90.705% |
| Genus plc | 6.4 Million USD | 149.504% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 132.52% |
| Pharming Group N.V. | -4.87 Million USD | 35.07% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -59.492% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -240.17% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 62.057% |
| ContraFect Corporation | -56.88 Million USD | 94.431% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 30.44% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -125.984% |
| IMV Inc. | -38.67 Million USD | 91.807% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -15.175% |
| MultiCell Technologies, Inc. | -722.81 USD | -438227.361% |
| ONE Bio Corp. | 13.68 Million USD | 123.157% |
| Accustem Sciences Inc. | -3.74 Million USD | 15.432% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 94.629% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -555.873% |
| Q BioMed Inc. | -3.44 Million USD | 8.049% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 189.499% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -20.58% |
| Biomind Labs Inc. | -1 Million USD | -213.814% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 94.237% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -9.204% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 52.343% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -69.938% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -10477.838% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 80.036% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -63.938% |
| GB Sciences, Inc. | -1.42 Million USD | -123.038% |
| Alpha Cognition Inc. | -9.7 Million USD | 67.356% |
| HST Global, Inc. | -140.9 Thousand USD | -2148.486% |
| CSL Limited | 3.7 Billion USD | 100.086% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -181.648% |
| Halberd Corporation | -75.05 Thousand USD | -4121.551% |
| Enzolytics Inc. | -2.14 Million USD | -47.444% |
| Agentix Corp. | -1.37 Million USD | -130.965% |
| Resverlogix Corp. | -12.74 Million USD | 75.149% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.255% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -203.475% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -8.523% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -100.606% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 6.952% |
| AVAX Technologies, Inc. | 6.69 Million USD | 147.338% |
| Zenith Capital Corp. | -8.94 Million USD | 64.573% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.238% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -18086.522% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -29.037% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1747.287% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -58.038% |
| Kadimastem Ltd | -3.04 Million USD | -4.211% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -221.962% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -152.251% |
| BioStem Technologies, Inc. | -7.77 Million USD | 59.271% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1645.75% |
| LadRx Corporation | -3.82 Million USD | 17.14% |
| Cell Source, Inc. | -4.32 Million USD | 26.751% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -361.209% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -361.209% |
| NovAccess Global Inc. | -2.46 Million USD | -28.439% |
| Affymax, Inc. | -15.04 Million USD | 78.943% |
| Itoco Inc. | -919.14 Thousand USD | -244.7% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 25.249% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -183.134% |
| Mobile Lads Corp. | -554.55 Thousand USD | -471.323% |
| CytoDyn Inc. | -18.05 Million USD | 82.455% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -12487.501% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1339.614% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -461.032% |
| SYBLEU INC | -149.18 Thousand USD | -2023.793% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -74.434% |
| International Stem Cell Corporation | -663 Thousand USD | -377.869% |
| Bioxytran, Inc. | -3.82 Million USD | 17.064% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5918.758% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -15476.568% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 91.264% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -95.814% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -330.569% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -1.841% |
| Neutra Corp. | -229.48 Thousand USD | -1280.596% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 81.936% |
| PureTech Health plc | -146.19 Million USD | 97.833% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 85.258% |
| IXICO plc | -1.43 Million USD | -120.478% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 66.618% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.399% |
| CSL Limited | 3.81 Billion USD | 100.083% |
| Cellectis S.A. | -108.85 Million USD | 97.09% |